Clinical Trials Browser

Phase 1 × tenalisib × Lymphoid × Clear all

NCT02567656 2020-01-13

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Phase 1 Completed

58 enrolled 15 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03471351 2019-12-27

Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL

Phase 1 Terminated

Hodgkin Disease

NCT02017613 2016-06-24

PI3K

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous